BCL2 and diffuse large B-cell lymphoma: One of the possible genes responsible for variable BCL2 inhibitor response is PMAIP1, in vitro studies have shown that DLBCL cells with amplifications of this gene are more sensitive to drugs like venetoclax (Liu et al., 2018).